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Abstract
Background: Multidrug-resistant Plasmodium is of major concern today. Effective vaccines or successful
applications of RNAi-based strategies for the treatment of malaria are currently unavailable. An unexplored area in
the field of malaria research is the development of DNA-targeting drugs that can specifically interact with parasitic
DNA and introduce deleterious changes, leading to loss of vital genome function and parasite death.
Presentation of the hypothesis: Advances in the development of zinc finger nuclease (ZFN) with engineered
DNA recognition domains allow us to design and develop nuclease of high target sequence specificity with a
mega recognition site that typically occurs only once in the genome. Moreover, cell-penetrating peptides (CPP) can
cross the cell plasma membrane and deliver conjugated protein, nucleic acid, or any other cargo to the cytoplasm,
nucleus, or mitochondria. This article proposes that a drug from the combination of the CPP and ZFN systems can
effectively enter the intracellular parasite, introduce deleterious changes in its genome, and eliminate the parasite
from the infected cells.
Testing the hypothesis: Availability of a DNA-binding motif for more than 45 triplets and its modular nature, with
freedom to change number of fingers in a ZFN, makes development of customized ZFN against diverse target
DNA sequence of any gene feasible. Since the Plasmodium genome is highly AT rich, there is considerable
sequence site diversity even for the structurally and functionally conserved enzymes between Plasmodium and
humans. CPP can be used to deliver ZFN to the intracellular nucleus of the parasite. Signal-peptide-based
heterologous protein translocation to Plasmodium-infected RBCs (iRBCs) and different Plasmodium organelles have
been achieved. With successful fusion of CPP with mitochondrial- and nuclear-targeting peptides, fusion of CPP
with 1 more Plasmodium cell membrane translocation peptide seems achievable.
Implications of the hypothesis: Targeting of the Plasmodium genome using ZFN has great potential for the
development of anti-malarial drugs. It allows the development of a single drug against all malarial infections,
including multidrug-resistant strains. Availability of multiple ZFN target sites in a single gene will provide alternative
drug target sites to combat the development of resistance in the future.
Background
Malaria is the most devastating human parasitic infec-
tion. It threatens half of the world’s population, killing
more than 1 million people each year [1,2]. Malaria spe-
cies vary widely in epidemiology and clinical manifesta-
tion [3,4]. No effective malaria vaccine is currently
available, and drug resistance has been implicated in the
spread and re-emergence of the disease [5-7]. Artemisi-
nin drugs, an essential component of treatment for
multidrug-resistant falciparum malaria, have recently
shown signs of decreased efficacy in combination drug
therapy [8-12].
With the availability of complete genome sequences of
Plasmodium, humans and Anopheles-hosts of the parasite,
development of novel effective anti malarial drugs was
envisioned [13]. However, in spite of eclipse of more than
one decade no significant advances have been made in the
area of genomics based anti-malarial drug development.
Plasmodium genome is highly AT rich as compared to
human genome and this opens up opportunities for devel-
opment of DNA-targeting drugs that can specifically inter-
act with parasite DNA and introduce deleterious changes
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any medium, provided the original work is properly cited.leading to loss of vital genome function and parasite death.
Some DNA targeting drugs such as Aminoquinolines, aza-
terphenyl diamidines, adozelesin and bizelesin shows anti
plasmodium activity, however the problem of cytotoxicity
and potential threat of mutagenesis in human DNA is
major limiting factor [14-16].
Presentation of the hypothesis
Advances in the development of zinc finger nuclease
(ZFN) with engineered DNA recognition domains allow
us to design and develop nuclease of high target
sequence specificity [17-19]. In vivo application of ZFN
with a single mega recognition sequence leads to target
gene modification in Drosophila, zebra fish, mice, Arabi-
dopsis, rice, tobacco, and other genomes [20-25], with a
gene targeting frequency upto 80% of ZFN-transfected
cells [26]. Cell-penetrating peptides (CPP) provide a
novel mechanism for intracellular macromolecular deliv-
ery [27,28], CPP are known to cross the cell plasma
membrane in a nonspecific manner and deliver conju-
gated protein, nucleic acid, or any other cargo to the
cytoplasm, nucleus, or mitochondria, depending on the
additional signal sequences present [27,29-33].
In this article it is believed that a drug from the
combination of CPP and ZFN can effectively enter the
intracellular parasite, introduce deleterious changes in
its genome, and eliminate the parasite from infected
cells. Preliminary studies of therapeutic application of
ZFN-based drugs against HIV and hepatitis B virus
further strengthen the prospects of ZFN-based anti-
malarial drug development [26,34]. ZFN mediated dis-
ruption of HIV co-receptor CCR5 in human CD4(+) T
cells confers resistance to HIV-1 infection [22,26,35].
While ZFN therapeutic against hepatitis B virus
intended to directly target and inactivate episomal
DNA viral genomes [34]. In the present article, the use
of ZFN to specifically target the Plasmodium genome
with the aim to knock out vital parasite genes is pro-
posed (Figure 1).
Key hypothesis/assumptions
1. ZFN will specifically target the Plasmodium
genome.
2. ZFN can cross the plasma membrane barrier of
the host and Plasmodium cell.
3. DNA double-strand break will kill Plasmodium.
Figure 1 CPP-ZFN. A. Plasmodium-targeting peptide having signal peptides for infected RBC penetration, merozoite import, and organelle
targeting, conjugated with Plasmodium specific zinc finger nuclease. B. It is hypothesized that the Plasmodium-targeting peptide will cross the
membrane barriers of RBC and Plasmodium, and ZFN will introduce a double-strand break in the vital gene of the Plasmodium genome (a, b),
leading to loss of gene function (c) and finally parasite death.
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Designing specific ZFN
ZFN can be designed specifically against any gene in any
genome [21,22,36-38]. C2H2-type zinc finger proteins
consist of an array of protein fingers stabilized by zinc
ion, with each finger recognizing a specific triplet of
DNA sequence [17]. Protein fingers specific for more
than 45 triplets are known and have a modular nature,
with freedom to change number of fingers, which makes
the development of customized ZFP against diverse tar-
get DNA sequence feasible (Additional file 1). A combi-
nation of 6 fingers recognizes a DNA sequence of 18
nucleotides that have a probability of occurring after 4
18
nucleotides, much more than the human genome size
(3000 MB). Hence, a ZFN designed against the Plasmo-
dium genome have negligible probability of randomly
occurring in the human genome. ZFN designing and
validation tools, and CompoZr® custom ZFN designing,
assembling, and validation service, reduce the time
required for the development of ZFN against new tar-
gets [39-42].
Selection of ZFN target sites
Availability of complete genome sequences have helped
identify different anti-malarial drug targets, such as his-
tone deacetylase, aspartic proteases or plasmepsins, ami-
nopeptidases, and the purine salvage enzyme
hypoxanthine-xanthine-guanine phosphoribosyltransfer-
ase, within the parasite [43-46]. However, limited
knowledge on the structure of most of these genes, and
on the conservation of basic eukaryotic cellular machin-
ery in Plasmodium and humans, hampers the conven-
tional enzyme-targeting drug design procedures [47].
The Plasmodium genome is highly AT rich, in contrast
to the human genome that is GC-rich; this provides
considerable sequence (ZFN target) site diversity even
for the structurally and functionally conserved enzymes
between Plasmodium and humans. ZFN technology can
utilize this sequence diversity and overcome the limita-
tions of traditional drug-design approaches, which are
confined to parasite-specific metabolic pathways. More-
over, ZFN can be designed against the target site con-
served across different Plasmodium species (Additional
file 2).
Delivery of ZFN to the target site
Discovery of cell-penetrating peptides provides a novel
way of delivering therapeutic molecules to the target cell
or organelles [27-29,31,48-51]. A major challenge in
ZFN delivery is developing a peptide that can transfer
conjugated ZFN through cell membranes of Plasmo-
dium-infected RBC (iRBC), the parasite, parasitophorous
vacuole, and its organelles (apicoplast, mitochondria, or
nucleus).
Delivery to RBCs
CPP are generally considered to deliver cargo to cells in
a nonspecific manner [51]. iRBCs have different surface
proteins and charge that can be utilized for making stra-
tegies for specific ZFN delivery. As a matter of evidence,
P1 peptides specifically target iRBCs [52], and DPT-sh1/
sh2 CPP specifically recognize and deliver conjugated
heterologous proteins to iRBCs [53].
Translocation from host cell cytoplasm to Plasmodium
Following CPP-mediated ZFN delivery to RBCs, the next
challenge is to cross the parasite cell membrane and
interact with its DNA. CPP-mediated protein delivery to
different intracellular organelles such as the nucleus and
mitochondria have been reported [54,55]. Intracellular
Plasmodium imports a number of proteins, such as
heme, δ-aminolaevulinate (ALA), and peroxiredoxin 2,
from the host cytoplasm [56-58], which could be a valu-
able source of signal sequences for translocation of ZFN
from the host cytoplasm to the parasite.
Targeting to Plasmodium organelles
Once ZFN enters the Plasmodium, it has to be directed
towards any of its organelles-apicoplast, mitochondria,
or nucleus-which have their own genome. Use of the
yeast GAL4 nuclear localization signal leads to translo-
cation of green florescent protein (GFP) to Plasmodium
nucleus and shows conservation of nuclear localization
signal in Plasmodium and other eukaryotes [59]. GFP
was fused with the N-terminal sequence of heat shock
protein (PfHsp); PfHsp-GFP was targeted to Plasmo-
dium mitochondria [60]; and apicoplast targeting was
achieved by using the signal sequence of acyl carrier
protein [61-63].
Availability of iRBCs penetrating peptide [53]; Plasmo-
dium import proteins [56-58]; and Plasmodium apico-
plast, mitochondria, and nucleus targeting signal
sequences [59-63] provides building blocks for the
development of a Plasmodium-targeting, multiple-mem-
brane-traversing peptide. Following the successful fusion
of CPP with mitochondrial- and nuclear-targeting pep-
tides [54,64,65], fusion of CPP with 1 more Plasmodium
cell membrane translocation peptide appears to be
achievable.
Hydrolysis of double-stranded DNA
A ZFN-induced double-strand break (DSB) triggers
either of the 2 DNA repair processes: error-prone non-
homologous end joining (NHEJ) and error-proof homol-
ogy-dependent repair (HDR). Genetic and biochemical
evidence support the hypothesis that NHEJ and HR are
2 independent and competing mechanisms for DSB
repair in diploid organisms[66,67]. Being in the haploid
stage in humans, HDR must be absent in Plasmodium
and the error-prone repair mechanism of NHEJ often
results in localized mutations due to deletion and/or
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resulting in disruption of functional gene expression in
Plasmodium. Moreover, AT-specific DNA alkylating
drugs have previously shown anti P. falciparum activity
and recent advances in ZFN directed multiple DSB
resulting in chromosomal deletions further strengthens
the prospects of DNA targeting anti malaria drug
[68-70].
Experimental validation of ZFN therapeutic efficacy
An in silico designed and in vitro validated ZFN is to be
evaluated for bioavailability, potency, in vivo localization
and their specificity for parasite over human DNA. A
microfluorimetric method using PicoGreen® can be used
for assessing susceptibility of parasites to CPP-ZFN
compounds [71,72]. Since all ZFN consist of nuclease
domain of FokI restriction enzyme so FokI antisera can
be used for immuno-localization and quantification of
ZFN [73]. Alternatively ZFN are designed to have an
additional small protein tag, such as Flag or His tag and
subsequently detected by fusion tag specific antibodies
[74]. The quantification of DSB repair loci induced by
ZFN provide genotoxicity assay, to test any off target
effect of parasite specific ZFN over human genome
[75,76].
Implications of the hypothesis
The major advantage of ZFN technology is that it enor-
mously increases the number of drug targets because it
can utilize the vast sequence diversity among structu-
rally and functionally conserved enzymes of human and
Plasmodium proteins. Prolonged use of any drug forces
the evolution of drug-resistant parasite strains, and ZFN
would not be an exception. Another advantage of ZFN
technology is that it allows convenient development of
new ZFN against other target sites (18 bp) in the same
gene. The resulting new drug will be effective even
against resistant strains, providing ample alternatives for
drug resistance management.
Unlike common drugs that directly inhibit the target
protein, ZFN technology is focused on inhibiting the
synthesis of a functional target protein; thus, its effect
will be slower than inhibitor drugs. This constraint may
not be a concern as ZFN utilizes the difference between
human and Plasmodium gene sequences, so every vital
gene becomes a potential drug target. Selection of geno-
mic locus coding for short half-life will greatly enhance
the response time of ZFN-based drugs.
Availability of newer drug targets to virtually all Plas-
modium g e n e sp r o v i d e st h eo p p o r t u n i t yt of i n dc o n -
served sites in vital genes and develop a single drug
against all malarial infections, including multidrug-resis-
tant strains, for worldwide use. CPP-mediated protein
delivery is an established method that can be used for
delivery of the newly designed ZFN. CPP-ZFN promises
to be a safe and sustainable drug for malaria intervention.
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Additional file 1: Designing of target-site-specific zinc finger
nuclease (ZFN) through modular assembly. With the target site
specific ZFP designing by incorporating zinc finger helices, linkers, N and
C-terminal fixed sequences, ZFP binding to target site can be validated
by gel shift assay. As ZFP do not have nuclease activity it does not cut
the target sequence. Incorporation of nuclease domain of FokI
constitutes the functional ZFN that can be validated by in vitro digestion
of DNA with target sequence.
Additional file 2: Designing of zinc finger nuclease (ZFN) against a
conserved site in lactate dehydrogenase genes of P. falciparum and
P. vivax. Two ZFN designed on opposite strands will introduce a nick in
the spacer region, leading to a double-strand break. ELISA data of multi-
target specificity assay for all triplets, black bars represent target
oligonucleotides, while white bars represent oligonucleotide pools with a
particular 5’ nucleotide. The height of each bar represents the relative
specificity of the protein for each target [42].
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